Cargando…

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes

Novel treatment modalities are required urgently in patients with hepatocellular carcinoma (HCC). A vaccine that induces cytotoxic T lymphocytes (CTLs) is an ideal strategy for cancer, and glypican-3 (GPC3) is a potential option for HCC. Blocking the programmed death-1 (PD-1)/PD-L1 pathway is a rati...

Descripción completa

Detalles Bibliográficos
Autores principales:	SAWADA, YU, YOSHIKAWA, TOSHIAKI, SHIMOMURA, MANAMI, IWAMA, TATSUAKI, ENDO, ITARU, NAKATSURA, TETSUYA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238729/ https://www.ncbi.nlm.nih.gov/pubmed/25354479 http://dx.doi.org/10.3892/ijo.2014.2737

Ejemplares similares

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
por: Fujinami, Norihiro, et al.
Publicado: (2016)

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
por: Nobuoka, Daisuke, et al.
Publicado: (2012)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
por: Charneau, Jimmy, et al.
Publicado: (2021)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer
por: SAWADA, YU, et al.
Publicado: (2014)

Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response
por: Mashima, Hiroaki, et al.
Publicado: (2020)

Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade
por: Aoki, Hiroyasu, et al.
Publicado: (2021)

Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides
Publicado: (1988)

Peptide-independent Recognition by Alloreactive Cytotoxic T Lymphocytes (CTL)
por: Smith, Pamela A., et al.
Publicado: (1997)

Time-lapse imaging assay using the BioStation CT: A sensitive drug-screening method for three-dimensional cell culture
por: Sakamoto, Ruriko, et al.
Publicado: (2015)

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
por: Kamata, Toshiko, et al.
Publicado: (2016)

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25(+) Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
por: Sutmuller, Roger P.M., et al.
Publicado: (2001)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes
Publicado: (1992)

Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes
Publicado: (1989)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Identification of a novel HLA-A(*)02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene
por: YOSHIMURA, MAYUKO, et al.
Publicado: (2014)

Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response
por: Sayem, Mohammad A., et al.
Publicado: (2015)

Antibiotic and cytotoxic peptides
por: Sewald, Norbert
Publicado: (2012)

Heat Shock Protein–Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity
por: Blachere, Nathalie E., et al.
Publicado: (1997)

Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells
por: Hoff, Antje, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_odi6bj6r630peukclbcjf44m32